Janus Henderson Group PLC Raises Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Janus Henderson Group PLC increased its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 12.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,866,755 shares of the biopharmaceutical company's stock after acquiring an additional 314,363 shares during the quarter. Janus Henderson Group PLC owned about 3.76% of Xenon Pharmaceuticals worth $112,425,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. Prudential Financial Inc. increased its stake in Xenon Pharmaceuticals by 177.7% during the 4th quarter. Prudential Financial Inc. now owns 39,000 shares of the biopharmaceutical company's stock valued at $1,529,000 after purchasing an additional 24,956 shares in the last quarter. Barclays PLC increased its stake in Xenon Pharmaceuticals by 1,275.5% during the 3rd quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company's stock valued at $590,000 after purchasing an additional 13,903 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in Xenon Pharmaceuticals by 12.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 238,522 shares of the biopharmaceutical company's stock valued at $9,350,000 after purchasing an additional 26,235 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Xenon Pharmaceuticals by 38.9% during the 4th quarter. JPMorgan Chase & Co. now owns 1,356,895 shares of the biopharmaceutical company's stock valued at $53,190,000 after purchasing an additional 380,112 shares in the last quarter. Finally, Avior Wealth Management LLC bought a new stake in Xenon Pharmaceuticals during the 4th quarter valued at about $101,000. 95.45% of the stock is currently owned by institutional investors.

Xenon Pharmaceuticals Price Performance

Shares of XENE traded down $0.17 on Thursday, reaching $29.57. The company's stock had a trading volume of 1,147,831 shares, compared to its average volume of 508,722. The stock has a market capitalization of $2.26 billion, a P/E ratio of -10.49 and a beta of 1.21. The stock's 50 day simple moving average is $34.28 and its two-hundred day simple moving average is $38.12. Xenon Pharmaceuticals Inc. has a 12-month low of $26.74 and a 12-month high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.90) by $0.07. The business had revenue of $7.50 million during the quarter, compared to analysts' expectations of $1.64 million. During the same period in the previous year, the business posted ($0.62) EPS. Analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on XENE. StockNews.com raised shares of Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Tuesday. William Blair reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Monday, May 5th. Wells Fargo & Company dropped their price target on shares of Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating on the stock in a report on Tuesday. Evercore ISI began coverage on shares of Xenon Pharmaceuticals in a report on Wednesday. They set an "outperform" rating and a $55.00 price target on the stock. Finally, Chardan Capital reaffirmed a "buy" rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $54.82.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.